Today: 22 May 2026
Fundrise VCX Stock Surges 55% After NYSE Debut as Retail Investors Chase Private AI
21 March 2026
2 mins read

Fundrise VCX Stock Surges 55% After NYSE Debut as Retail Investors Chase Private AI

NEW YORK, March 20, 2026, 19:38 EDT

Shares of Fundrise Innovation Fund surged for a second day on Friday, finishing at $117.70—a 54.5% leap from Thursday’s $76.16 close. The fund had just made its NYSE debut the previous day. Compared to its last reported net asset value as of March 2, which stood at $18.26 per share, the VCX price was trading at more than six times that figure.

That’s significant: VCX stands out as one of the rare listed vehicles giving retail investors a shot at private tech companies, while most of the AI surge remains out of reach in public markets. Fundrise puts 43.8% of the portfolio in artificial intelligence as of Feb. 15, led by Anthropic, Databricks, and OpenAI. Private companies made up 85% of the fund.

The fund was eyeing a direct listing on or after March 10, allowing current shares to trade publicly without bringing in fresh capital. That timeline got pushed back, after the Iran war shook markets, ramped up volatility, and snarled shipping through the Strait of Hormuz, according to the Wall Street Journal this week. In the end, the launch went ahead anyway—suggesting there was enough demand to overlook the macro shock and grab a piece of private AI exposure.

VCX operates as a closed-end fund, meaning it issues a set number of shares that are bought and sold on an exchange at market prices—prices that can diverge from the underlying asset value. According to Investor.gov, this kind of structure often suits less liquid assets like stakes in private companies. Still, investors might find themselves paying a premium above NAV.

Fundrise is framing its rollout as a push to make private markets accessible for smaller investors. In a March 3 statement, Chief Executive Ben Miller said VCX aims to let “anyone, regardless of net worth” invest in private tech firms. The company expects the fund to debut with over 100,000 investors and around $650 million in net assets. Business Wire

The setup could be exaggerating the action. Back in January, proxy filings stated anyone picking up shares before March 1 would face a six-month lockup—a move the board pitched as a way to limit initial selling and let the market settle on a price range. On Thursday, NYSE data show VCX triggered a volatility halt.

Listed peers haven’t exactly offered a smooth ride. Robinhood’s $658.4 million RVI, which kicked off trading March 6 at $25 per share, set the tone. Destiny Tech100, another listed fund with private tech holdings, showed up at a 25.2% premium to NAV as of March 19, CEF Connect data shows. Morningstar’s Jack Shannon, quoted by Reuters on DXYZ’s 2024 rally, put it bluntly: investors should “stay on the sidelines.” Reuters

Here’s the risk in plain terms: according to the Investment Company Institute, traditional closed-end funds might swing above or below their NAV, all hinging on how the market feels or what investors are thinking at the moment. That means if sentiment cools off, late buyers are on the hook—premiums can vanish quicker than the underlying portfolio can keep up.

Stock Market Today

  • Q1 Earnings Review: Azenta Falls; West Pharmaceutical Leads Drug Development Services Stocks
    May 21, 2026, 9:31 PM EDT. Drug development inputs and services stocks, essential for pharmaceutical research and manufacturing, reported mixed Q1 results. Azenta (NASDAQ:AZTA), specializing in biological sample management, posted disappointing results with $144.8 million revenue, missing estimates and the weakest among peers, causing its share price to drop 23.4% to $17.65. Conversely, West Pharmaceutical Services (NYSE:WST), maker of specialized packaging and delivery devices, delivered a strong quarter with $844.9 million revenue, beating estimates by 8.4%. Overall, the sector's revenues beat consensus by 1.6%, despite an average 2.5% share price decline post-earnings. Tailwinds include growth in biologics and gene therapies, while headwinds feature pricing pressure and regulatory risks.

Latest articles

OpenAI Shares Hype Returns, Still No Ticker in Sight

OpenAI Shares Hype Returns, Still No Ticker in Sight

22 May 2026
OpenAI is preparing to confidentially file for a U.S. IPO, aiming to go public as early as September, sources told Reuters. The move follows a court win against Elon Musk, removing a key legal obstacle. Private-market share prices for OpenAI ranged from $658.94 to $732.38 this month, but no official public price exists. Ordinary investors still cannot buy OpenAI stock on public exchanges.
Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

22 May 2026
Estée Lauder and Spain’s Puig ended merger talks that would have created a $40 billion beauty group. Estée Lauder shares rose about 10% in after-hours trading, closing the regular session at $78.91. The company said it will focus on its turnaround plan and continue reviewing possible acquisitions or divestitures.
WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

22 May 2026
WhiteFiber shares jumped 22.2% to $29.55 after announcing a five-year AI compute contract worth over $160 million for a Paris-region deployment using NVIDIA GPU systems. Google Finance showed the stock rising further after hours. The project is backed by planned financing and 12 months of customer prepayments, but funding and execution remain pending. Service is expected to start in July, subject to equipment delivery and acceptance.
USPS Warns It May Not Deliver Mail Next Year Unless Congress Acts on Cash Crisis
Previous Story

USPS Warns It May Not Deliver Mail Next Year Unless Congress Acts on Cash Crisis

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

Stock Market Today 21.03.2026

Go toTop